Brenzys fails to bite

Brenzys has failed to make more than a small dent in its reference biologic Enbrel's R/PBS income, the biosimilar's takings growing to just six per cent of total etanercept reimbursements in four months.

Listing in December 2017 after being recommended for a-flagging against Pfizer's Enbrel, MSD's Brenzys made just over $200,000 from 198 scripts to March.

In comparison, Pfizer's ageing biologic Enbrel pulled in more than $4.6 million from 4,576 scripts, indicating the biosimilar competitor is making only a small impact on its R/PBS gross earnings.